Nautilus Biotechnolgy

NAUT

Market cap $270M

2.12 USD

+0.07

3.41%

At close Updated Oct 14, 1:57 PM EDT

1 day

3.41%

5 days

6%

1 month

133.92%

3 months

21.14%

6 months

-30.72%

Year to date

10.99%

1 year

125.41%

5 years

-63.51%

10 years

-79.69%

About: Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

Employees: 130

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 66.7%

Negative 16.7%

Voyager Will Take Center Stage In Nautilus' Commercial Push

Nautilus Biotechnology is pivoting to a proteoform-focused strategy, prioritizing technically validated, commercially demanded assays over broad-scale proteomics. NAUT's near-term upside hinges on successful execution of the Voyager platform launch and proteoform assay commercialization, with key catalysts expected in 2027. Financially, NAUT maintains a stable burn rate, with $129.2 million in cash providing runway into 2028 and reducing immediate dilution risk.

Voyager Will Take Center Stage In Nautilus' Commercial Push

Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms

First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas

Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization roadmap. But their roadmap with Voyager is clearer, although Early Access revenue remains too limited to prove it can turn into recurring sales. Unfortunately, the main risks going forward are still tied to potential execution setbacks, its ongoing cash burn, and a likely capital raise by 2027.

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback

Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript

Nautilus Biotechnology Q2 Earnings Call Highlights

Nautilus Biotechnology NASDAQ: NAUT said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its Broadscale broad-proteome program.

Nautilus Biotechnology Q2 Earnings Call Highlights

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights Recognized first revenue in the second quarter of 2026, including grant revenue from the Michael J.

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m.

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

3 Small-Cap Stocks to Buy Before May 15

Don't rule out the possibility of rate cuts helping smaller companies in 2026.

3 Small-Cap Stocks to Buy Before May 15

Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript

Nautilus Biotechnology Reports First Quarter 2026 Financial Results

SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.

Nautilus Biotechnology Reports First Quarter 2026 Financial Results

See News Rankings

Price charts implemented using Lightweight Charts™